BJH - volume 16, issue 1, february 2025
E. Dewulf MSc
During ASH 2024, the role of autologous stem cell transplantation (ASCT) for patients with mantle cell lymphoma (MCL) was questioned in the TRIANGLE and ECOG-ACRIN EA4151 trials. In addition, the ENRICH trial evaluated the efficacy and safety of a chemotherapy-free regimen for older patients with untreated MCL. Regarding diffuse large-B-cell lymphoma (DLBCL), extended follow-up data of the POLARIX trial were presented, comparing R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone) to pola-R-CHP (polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisone) as first-line treatment. Also, the addition of the bispecific antibody glofitamab to R-CHOP or pola-R-CHP was evaluated in the COALITION trial, including younger patients with high-risk DLBCL. Finally, interim results of the DALY II trial were presented, assessing the feasibility, safety and efficacy of chimeric antigen receptor T (CAR T)-cell therapy with zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL.
(BELG J HEMATOL 2025;16(1):41–6)
Read moreBJH - 2025, issue Special, april 2025
E. Dewulf MSc
At the 2025 BHS GAM meeting, Dr. Toine Mercier (AZ St Maarten/KU Leuven, Belgium) explored the challenges of diagnosing and treating complex infections in haematology. His presentation highlighted diagnostic uncertainty, evolving treatment strategies, and the need for a multidisciplinary approach. He also discussed emerging diagnostic tools and novel antifungal therapies that may improve patient outcomes.
Read moreBJH - 2025, issue Special, april 2025
E. Dewulf MSc
During the BHS meeting, Elke Stienissen (president Lymfeklierkanker Vereniging Vlaanderen vzw & chair BHS patient committee), Marijke Quaghebeur (nurse specialist UZ Ghent & member BHS nurses committee) and Dr. Marc André (haematologist CHU UCL Namur & BHS president) presented the Belgian results of the 2024 Global Patient Survey on Lymphomas and CLL. The survey aimed to assess the needs and challenges faced by lymphoma patients and their caregivers.1 During the presentation, the speakers focused on the results related to diagnosis and symptoms, healthcare information, treatment and care, and psychosocial impact.
Read moreBJH - 2025, issue Special, april 2025
E. Dewulf MSc
During the 2025 BHS General Annual Meeting (GAM), the highlights session on lymphoma provided key insights into evolving management strategies for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Dr. Catherine Thieblemont (Hôpital Saint-Louis Paris, France) presented an in-depth overview of the latest approaches in DLBCL treatment. Consequently, Dr. Vibeke Vergote (UZ Leuven, Belgium) shared her perspective on the contemporary management of MCL, incorporating recent clinical trial data and emerging therapeutic options. Their discussions underscored the rapid advancements in lymphoma treatment and the shifting paradigms that are shaping patient care in 2025.
Read more
Top
